SHENZHEN, China, March 3 /PRNewswire/ -- Shenzhen Beike Biotechnology Co.,
Ltd. has announced the successful treatment with umbilical cord stem cells of
the youngest stroke patient ever to undergo such a procedure. The
announcement was made following a two-month evaluation period by physicians in
her native country, Hungary, to verify the positive results.
Starting from October 28th, Beike provided umbilical cord stem cells to
the Nanshan People's Hospital for the treatment of a four-month-old Hungarian
baby girl named Timea Gresco, who had suffered a stroke when she was
delivered three months prematurely. Umbilical cord stem cells were delivered
intravenously over a two-month time period. Due to national regulations, the
baby could not receive such treatment in her own country so her mother,
Judit Godo, traveled to Shenzhen with her husband and daughter.
Treatments for leukemia and other diseases with umbilical cord blood stem
cells have been performed for years. However, the treatment of stroke patients
and those with other neurological diseases with stem cells from human
umbilical cords has become increasingly popular only recently. Today,
treatments for neurological diseases using umbilical cord blood is being taken
forward by countries outside the United States, including China, as FDA
approval takes longer.
Timea was born on July 16th, 2005 and immediately suffered a stroke - with
bleeding on the left side of her brain causing significant brain damage. She
was able to move all of her limbs, but the left limbs had significantly less
strength than the right and the doctors predicted she would have both physical
and mental impairment including possible paralysis when older. When she
finished her treatment, all her limbs had gained strength with the left having
nearly the same strength as the right.
"At first we were doubtful about Timea getting stem cell treatments in
China. Over time, our doubt turned into curiosity," said Timea's physician in
Hungary. "Time will tell but we were quite surprised to see how active the
baby was upon her return from China. This is not common for babies with such
severe brain damage."
Mrs. Godo said, "As a mother, I knew Timea was getting improvement as soon
as she stopped crying after the first injection, but it was reassuring to see
such a positive reaction from the medical staff when I returned home.
"Before the treatment, Timea was crying all the time, never smiled and
would not acknowledge you if you smiled or waved at her. After the treatment,
she stopped crying, started smiling a lot, smiles back at you - even through a
mirror, and has a healthy appetite which she did not before. All her limbs
were stronger and her affected arm and leg have become almost as strong as her
healthy ones. After coming home, her head control keeps improving and she no
longer keeps her head to one side," said Ms. Godo.
Dr. Sean Hu, chairman of Beike, said, "We were all very happy to see the
improvement. In theory, the younger you are when you receive stem cell
treatments, the more effective, but we were excited to see such positive
results so quickly. This is the youngest patient we have treated and while we
can't say positively, as far as we know, this is the youngest patient in the
world treated for stroke with umbilical cord blood stem cells. We look forward
to having Timea back for another treatment before she turns one."
About Beike Biotech Company Limited
Beike is a biotechnology company that was founded with capital from
Beijing University, Hong Kong University of Science and Technology and
Shenzhen City Hall. It is also supported with funds from the China State
National Fund. The research and clinical work is a collaboration of Beijing
University, Hong Kong University of Science and Technology, No. 3 Army Medical
University, Zhongshan Medical University, Guiyang Medical College and
Zhengzhou University.
For more information on Beike and before and after videos,
see: http://www.beikebiotech.com.
(http://www.stemcellschina.com/index.php?option=com_content&task=view&id=6&Ite
mid=22 in China)
Contact:
Dr. Sean Hu - Chairman
Beike Biotech Co., Ltd.
Shenzhen Hi-Tech Industrial Park
+8613823501818
info@beikebiotech.com
This release was issued through eReleases(TM). For more information,
visit http://www.ereleases.com.
SOURCE Beike Biotechnology Co., Ltd.
 back to top
Related links:
http://www.beikebiotech.com
CONTACT:
Dr. Sean Hu, Chairman, Beike Biotech Co.,
Ltd., Shenzhen Hi-Tech Industrial Park, +8613823501818,
info@beikebiotech.com
|
